Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02638948 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 508
- Enrollment target
NCT02638948 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 508 participants.
The verdict
NCT02638948, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 508 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the study drug, BMS-986142, is safe and effective in treating moderate to severe rheumatoid arthritis in subjects with an inadequate response to methotrexate or methotrexate and up to 2 tumour necrosis factor (TNF) Inhibitors. Patients who qualify will be randomized to either one of 3 doses of BMS-986142 or placebo in 1:1:1 randomization for 12 weeks. Disease activity and safety will be assessed over the course of the study.
Interventions
- DRUG Placebo
- DRUG Methotrexate
- DRUG BMS-986142
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2016-02-16 |
| Est. Completion | 2018-05-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02638948
The ClinicalTrials.gov registry entry for NCT02638948 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 508 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02638948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02638948 about?
NCT02638948 is a clinical study titled "Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis". The purpose of this study is to determine whether the study drug, BMS-986142, is safe and effective in treating moderate to severe rheumatoid arthritis in subjects with an inadequate response to methotrexate or methotrexate and up to 2 tumour necrosis factor (TNF) Inhibitors. Patients who qualify wi...
What is the current status of trial NCT02638948?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 508 participants. The study started on 2016-02-16. Estimated completion is 2018-05-03.
What interventions are being tested in trial NCT02638948?
The interventions under investigation include: Placebo (DRUG), Methotrexate (DRUG), BMS-986142 (DRUG).
Who is sponsoring clinical trial NCT02638948?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.